| Study Period | 2021 - 2032 |
| Market Size in 2025 | USD 4.7 Billion |
| Market Size in 2026 | USD 5.0 Billion |
| Market Size by 2032 | USD 8.1 Billion |
| Projected CAGR | 8.3% |
| Largest Region | North America |
| Fastest-Growing Region | Asia-Pacific |
| Market Structure | Fragmented |
Explore the market potential with our data-driven report
The clinical trial biorepository & archiving solutions market size was USD 4.7 billion for 2025, and it will grow by 8.3% during 2026-2032, to reach USD 8.1 billion by 2032.
The market expands because the pharmaceutical and biotechnology industries rapidly accelerate their research output and require specialised infrastructure to manage complex biological materials. To safely manage this massive volume of experimental materials, research organisations actively outsource sample storage and tracking to third-party biobanking providers. Consequently, these specialised archiving solutions successfully reduce operational burdens, ensure strict regulatory compliance, and drive the continuous advancement of personalised medicine.
The biopharmaceutical industry increasingly outsources the storage and management of clinical trial samples to specialised third-party providers. Pharmaceutical and biotechnology companies rely on these organisations to maintain strict temperature controls, track biological specimens, and manage regulatory documentation across multi-site clinical studies. The scale of global research activity continues to expand rapidly. According to ClinicalTrials.gov, the number of registered clinical studies worldwide exceeded 560,000 in 2025, generating substantial volumes of biological samples and associated research data. The International Vaccine Institute launched a centralised biorepository capable of preserving up to 4 million biological samples in 2025, reflecting the large-scale infrastructure required to support expanding clinical research programmes. Consequently, specialised providers increasingly combine physical storage capacity with digital sample management systems.
The global clinical trial biorepository market expands because pharmaceutical developers increasingly conduct research to address complex and rare diseases. Drug manufacturers actively investigate novel therapies for chronic conditions, genetic disorders, and advanced cellular treatments. According to the World Health Organization, more than 300 million people globally live with rare diseases, creating strong demand for new therapeutic development. These large-scale research programs generate substantial volumes of biological samples and associated research data that must be preserved over long study periods. As clinical trials become more complex and data-intensive, research institutions increasingly rely on specialised biorepository facilities and digital archiving systems to maintain sample integrity and ensure organised regulatory documentation.
A key restraint in the clinical trial biorepository and archiving solutions market is data reliability and operational complexity. Biorepositories are critical for storing biological samples and associated clinical data during trials, but ensuring sample integrity across diverse patient populations and long-term storage periods is complex. Temperature fluctuations, equipment failure, and improper sample handling can compromise sample quality and produce inaccurate trial results.
High infrastructure and maintenance costs compound these operational constraints. Establishing advanced biobanking facilities requires significant capital investment. Ultra-low temperature freezers cost between USD 7,000 and USD 35,000 per unit, and large repositories storing tens of thousands of samples can cost USD 3–5 million or more to set up. Liquid nitrogen storage systems, automated sample handling infrastructure, and secure digital archiving platforms add further to the initial outlay. Ongoing operational expenses for energy, monitoring, maintenance, and specialized personnel reach hundreds of thousands of dollars annually. These financial demands limit adoption among smaller research institutions and emerging biotech companies.
Stem cells are the largest category, holding a market share of 45% because modern drug developers increasingly utilise these versatile cells in regenerative medicine and advanced cell therapies. These highly sensitive biological materials require strict cryogenic storage conditions to maintain long-term viability. The World Marrow Donor Association reports approximately 43.7 million registered stem cell donors globally. This massive global donor network reflects the extensive infrastructure required to collect, process, and preserve stem-cell-related biological materials across international research programmes.
Human tissue is the fastest-growing category during the forecast period, because biomedical researchers increasingly rely on patient-derived biological specimens to study disease progression and evaluate treatment responses. Clinical investigators analyse tissue samples to identify biomarkers, understand tumour biology, and assess therapeutic effectiveness. According to the National Institutes of Health, the ClinicalTrials.gov registry surpassed 500,000 registered clinical studies globally in 2024. Large-scale clinical research programs generate substantial volumes of patient-derived biospecimens that must be securely preserved and organised within specialised biorepository facilities.
The products analysed in this report are:
Phase III is the largest category, capturing a market share of 45%, because these advanced clinical trials involve large patient populations across multiple international sites and extend over long timeframes. Such late-stage trials generate substantial volumes of biological samples along with complex regulatory documentation required for final market approval. According to the European Medicines Agency, 114 new human medicines were recommended for marketing authorisation in 2024. The steady progression of therapies through final regulatory evaluation generates significant volumes of biological samples that require specialised biorepository storage systems and long-term data archiving.
Phase II is the fastest-growing category during the forecast period, because the global pharmaceutical research pipeline continuously advances experimental drugs into mid-stage safety and efficacy evaluations. These studies generate extensive biological samples and complex regulatory documentation that must be preserved throughout the trial lifecycle. The immense global clinical trial pipeline continuously feeds new therapies into Phase II development, creating sustained demand for structured sample storage and reliable clinical data archiving.
The phases analysed in this report are:
Biorepository services are the larger category, holding a market share of 85%, because clinical research generates a large quantity of biological samples that must be stored under controlled temperatures and strict safety requirements. Pharmaceutical companies rely on these facilities to collect, preserve, and store biological samples throughout the clinical research process across different study sites. The International Agency for Research on Cancer (IARC)’s biobank maintained more than 6 million biological samples from international collaborative studies in 2024, highlighting the large-scale storage infrastructure required to support global biomedical research activities.
Archiving solutions is the faster-growing category during the forecast period, because modern clinical research generates extremely large volumes of biological and genomic data that must be securely preserved for regulatory compliance. Digital archiving platforms enable researchers to organise documentation, track genetic datasets, and retrieve information across extended research timelines. The rapid expansion of biological datasets drives strong demand for advanced digital archiving platforms capable of securely managing large-scale clinical research information.
The offerings analysed in this report are:
Drive strategic growth with comprehensive market analysis
North America holds the largest share, of 40% of the global market, as it has many pharmaceutical companies, CROs and biobanks. It is required to provide accurate documentation during the clinical trial process in North America and to maintain samples for extended periods of time. Many research institutions have complex studies with multiple sites that produce large amounts of biological samples.
The need for professional storage, tracking and archival services will be consistent due to the high volume of biological samples produced from clinical trials. There is significant collaboration between the academic laboratories and drug development organisations within North America therefore, there are continual clinical research activities being performed. The continued clinical research activity supports the ongoing use of advanced biorepositories and data archives.
The United States dominates the global market as it is the biggest worldwide hub for pharmaceutical innovation and clinical research. The country continues to produce a large number of novel therapeutics supported by extensive research infrastructure and strong regulatory activity. According to the U.S. Food and Drug Administration, 50 novel drugs were approved in 2024, reflecting the high level of pharmaceutical development taking place in the country. The strong pace of drug development and regulatory approvals generates substantial volumes of clinical research data and biological samples throughout the development process. As a result, research institutions and pharmaceutical companies require secure storage infrastructure and reliable long-term archiving systems to manage clinical trial samples and associated research data.
Canada continues to strengthen its biomedical research and clinical trial ecosystem, supported by advanced healthcare infrastructure. The country also faces a substantial burden of chronic diseases that require ongoing research and therapeutic development. According to the Canadian Cancer Society, approximately 247,000 new cancer cases were diagnosed in Canada in 2024. As oncology research expands, large volumes of biological specimens, such as blood, tissue, and DNA samples, must be collected, preserved, and analysed. This growing research activity increases demand for specialised biorepository storage and long-term data archiving services.
Asia-Pacific has the highest CAGR of 9.0%, due to a significant expansion of clinical trial capacity and investment in modern healthcare systems across the region by various governments. The rapid growth of pharmaceutical and biotechnology companies and the associated increase in the number of experimental treatments being studied will continue to drive this trend. Additionally, government support for biomedical research programs and laboratory construction, along with an increase in local trials, will increase the demand for biobanking and archival services. International drug sponsors have begun to conduct more trials in the region as well.
China represents the largest country market in APAC because the country is rapidly expanding its pharmaceutical research and biotechnology development capabilities. Government initiatives strongly encourage domestic innovation and accelerate the development of new therapeutics. The National Medical Products Administration approved 48 first-in-class innovative drugs in 2024. The increasing number of novel therapies reaching regulatory approval reflects the large volume of clinical research and drug development activities conducted across the country. Consequently, research institutions require advanced specimen storage infrastructure and secure data archiving systems to support these expanding clinical studies.
India represents a rapidly growing national market because domestic hospitals, research institutions, and contract research organisations are increasingly expanding their clinical research activities. Global pharmaceutical companies conduct clinical trials in the country to access its large and diverse patient population. The Indian Council of Medical Research recorded 1,533,055 new cancer cases in 2024. The growing burden of complex diseases drives extensive clinical investigations to develop targeted therapies. As a result, research institutions require organised biorepository infrastructure and secure digital archiving systems to preserve biological samples generated during these studies.
Europe remains an important market due to its well-established pharmaceutical research ecosystem and strict clinical trial governance frameworks. Many multinational studies are coordinated through research centres and universities across the region. This generates a steady flow of patient samples that must be preserved under regulated conditions. Pharmaceutical collaborations and cross-border clinical studies are common here, which increases the need for reliable specimen logistics and long-term study documentation storage. Additionally, European regulators require detailed data retention and traceability during drug development, supporting the demand for structured archiving and specialised sample storage facilities.
The regions and countries analysed in this report are:
The market is fragmented because many types of service providers operate in this space, including specialised biobanks, contract research organisations, laboratory service firms, and data archiving technology vendors. No single company controls a dominant portion of the industry. Pharmaceutical and biotechnology companies often choose partners based on storage capacity, geographic presence, regulatory expertise, and digital tracking capabilities. New entrants also continue to appear as clinical research expands globally. In addition, regional service providers support local clinical studies, which further spreads market participation across numerous companies rather than concentrating it among a few large players.
Want a report tailored exactly to your business need?
Request CustomizationLeading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
Request the Free Sample Pages